Outcome domains and outcome measures used in studies assessing the effectiveness of interventions to manage non-respiratory sleep disturbances in children with neurodisabilities: A systematic review by McDaid C et al.
1McDaid C, et al. BMJ Open 2019;9:e027205. doi:10.1136/bmjopen-2018-027205
Open access 
Outcome domains and outcome 
measures used in studies assessing the 
effectiveness of interventions to manage 
non-respiratory sleep disturbances in 
children with neurodisabilities: a 
systematic review
Catriona McDaid,  1 Adwoa Parker,  1 Arabella Scantlebury,1 Caroline Fairhurst,1 
Vicky Dawson,2 Heather Elphick,3 Catherine Hewitt,1 Gemma Spiers,4 
Megan Thomas,  5 Bryony Beresford6
To cite: McDaid C, Parker A, 
Scantlebury A, et al.  Outcome 
domains and outcome measures 
used in studies assessing the 
effectiveness of interventions 
to manage non-respiratory 
sleep disturbances in children 
with neurodisabilities: a 
systematic review. BMJ Open 
2019;9:e027205. doi:10.1136/
bmjopen-2018-027205
 ► Prepublication history and 
additional material for this paper 
are available online. To view 
please visit the journal (http:// 
dx. doi. org/ 10. 1136/ bmjopen- 
2018- 027205).
Received 10 October 2018
Revised 25 February 2019
Accepted 14 May 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Catriona McDaid;  
 catriona. mcdaid@ york. ac. uk
Research
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY. 
Published by BMJ.
AbstrACt
Objectives To assess whether a core outcome set 
is required for studies evaluating the effectiveness of 
interventions for non-respiratory sleep disturbances in 
children with neurodisabilities.
Design Survey of outcome measures used in primary 
studies identified by a systematic review.
Data sources ASSIA, CENTRAL, Cochrane Database of 
Systematic Reviews, Conference Proceedings Citation 
Index, CINAHL, DARE, Embase, HMIC, MEDLINE, MEDLINE 
In-Process, PsycINFO, Science Citation Index, Social Care 
Online, Social Policy & Practice,  ClinicalTrials. gov, WHO 
International Clinical Trials Registry Platform and the UK 
Clinical Trials Gateway were searched up to February 
2017.
Eligibility criteria Studies evaluating pharmacological or 
non-pharmacological interventions for children (≤18 years 
old) with a neurodisability and experiencing non-
respiratory sleep disturbance.
Data extraction and synthesis Outcome measures were 
listed from each study and categorised into domains.
results Thirty-nine studies assessed five core outcome 
areas: child sleep, other child outcomes, parent 
outcomes, adverse events and process measures. There 
were 54 different measures of child sleep across five 
domains: global measures; sleep initiation; maintenance; 
scheduling; and other outcomes. Fifteen non-
pharmacological (58%) and four pharmacological studies 
(31%) reported child outcomes other than sleep using 29 
different measures. One pharmacological and 14 non-
pharmacological (54%) studies reported parent outcomes 
(17 different measures). Eleven melatonin studies (85%) 
recorded adverse events, with variation in how data were 
collected and reported. One non-pharmacological study 
reported an explicit method of collecting on adverse 
events. Several process measures were reported, related 
to adherence, feasibility of delivery, acceptability and 
experiences of receiving the intervention.
Conclusions There is a lack of consistency between 
studies in the outcome measures used to assess the 
effectiveness of interventions for non-respiratory sleep 
disturbances in children with neurodisabilities. A minimum 
core outcome set, with international consensus, should be 
developed in consultation with parents, children and young 
people, and those involved in supporting families.
PrOsPErO registration number CRD42016034067
IntrODuCtIOn
Child sleep problems are associated with 
poorer educational outcomes and daytime 
behaviour difficulties1 as well as having a 
negative impact on parents, such as height-
ened levels of parental stress and irritability.2 
Sleep disturbance can impact on all members 
of the family and it is often the parents’ 
own poor sleep quality which leads to them 
seeking help with their child’s sleep.3 Sleep 
disturbances are more common and severe 
in children with neurodisabilities compared 
with typically developing children.4 5 A recent 
national research prioritisation exercise 
ranked management of sleep disturbance for 
this group of children in the top ten research 
priorities.6 
strengths and limitations of this study
 ► Includes multiple interventions and populations thus 
providing a comprehensive overview of outcome 
measurement in this field.
 ► Provides data to inform the first stage of develop-
ment of a core outcome set.
 ► The study provides efficient use of data from an 
existing review but some outcomes that were out-
side the scope of our effectiveness review may have 
been missed.
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In response to a commissioned call from the UK 
National Institute for Health Research (NIHR), we 
undertook a systematic review, to evaluate the effective-
ness of pharmacological and non-pharmacological inter-
ventions for children with neurodisabilities experiencing 
non-respiratory sleep disturbances. The NIHR commis-
sioning brief requested a broad systematic review to ‘take 
stock’ of the current available evidence in order to inform 
future research.
One of the challenges we faced while undertaking the 
review was the diversity of outcomes assessed across the 
included studies, possibly a reflection of the fact that 
there is no agreed set of outcomes recommended for 
use in trials assessing the effectiveness of interventions in 
this field of research. Based on searches of the COMET 
database (http://www. comet- initiative. org/ (accessed 21 
June 2017)) there is no core outcome set in relation to 
children with neurodisabilities or typically developing 
children who experience non-respiratory sleep distur-
bances. A core outcome set is an agreed minimum, stan-
dardised set of outcomes that should be measured and 
reported in randomised controlled trials (RCTs) for a 
specific clinical area.7 They are required to maximise 
comparability across studies in a specific field in order 
to facilitate quantitative and narrative synthesis, reduce 
selective outcome reporting in studies of effectiveness 
and increase the relevance of results from primary studies 
and systematic reviews.7 An important first step, if there is 
not a core outcome set in a field, is to establish whether 
one is needed.8 The breadth of our review, covering both 
pharmacological and non-pharmacological interven-
tions provided an opportunity to explore whether a core 
outcome set is required.
The results of the systematic review of effectiveness 
are available separately ( www. journalslibrary. nihr. ac. 
uk/ programmes/ hta/ 1421202/#/).9–11 The aim of this 
paper is to summarise the outcome measures used in the 
RCTs and other effectiveness studies evaluating pharma-
cological and non-pharmacological interventions for the 
management of non-respiratory sleep disturbances in 
children with neurodisabilities and make recommenda-
tions about whether a core outcome set is required.
MEthODs
We used the included studies from our systematic review 
of treatment effectiveness which was based on a prospec-
tively registered review protocol. A summary of the 
methods relevant to this paper is provided.
Databases searched
We searched the following without language restrictions 
up to February 2017: Applied Social Science Abstracts 
& Indexes (ASSIA), The Cochrane Central Register of 
Controlled Trials (CENTRAL), Cochrane Database of 
Systematic Reviews (CDSR), Conference Proceedings 
Citation Index, Cumulative Index to Nursing & Allied 
Health (CINAHL), Database of Abstracts of Reviews of 
Effects (DARE), Embase, Health Management Infor-
mation Consortium (HMIC), MEDLINE, MEDLINE 
In-Process, PsycINFO, Science Citation Index, Social 
Care Online, Social Policy & Practice,  ClinicalTrials. gov, 
WHO International Clinical Trials Registry Platform 
and the UK Clinical Trials Gateway. The search strategy 
for ASSIA is in online supplementary file 1. The search 
results were loaded into EndNote bibliographic software 
(V.17.0.2.7390, Clarivate Analytics (formerly Thomas 
Reuters), Philadelphia, PA, USA).
study selection
One researcher screened titles only to remove obviously 
irrelevant records (10% checked by a second researcher), 
two researchers then independently screened abstracts 
and ordered potentially relevant papers, the full papers 
were screened independently by two researchers. We 
included studies of children and young people (≤18 years 
old) with neurodisability, experiencing non-respiratory 
sleep disturbances, which evaluated pharmacological 
(melatonin, clonidine and antihistamines) or non-phar-
macological Interventions (eg, behavioural, cognitive-be-
havioural, self-help resources, complementary therapies). 
We used the Morris et al definition of neurodisability as 
‘congenital or acquired long-term conditions that are 
attributed to impairment of the brain and/or neuro-
muscular system and create functional limitations’.12 A 
best available evidence approach was used with non-ran-
domised controlled studies and before and after studies 
included where RCT evidence was not available.
Outcomes
A broad range of outcomes were of interest:
Primary outcomes: child sleep-related outcomes 
(including parent/carer and child reported outcomes 
(eg, using sleep diaries and actigraphy), parent sleep-re-
lated outcomes (eg, quality of sleep) and measures 
of perceived parenting confidence, efficacy or under-
standing of sleep/sleep management (which can be a 
specific focus of parent training/behavioural interven-
tions which seek to change how parents manage sleep 
disturbance).
Secondary outcomes: child-related quality of life, daytime 
behaviour and cognition; parent/carer outcomes such as 
quality of life and well-being, physical well-being, mental 
well-being; family functioning; and adverse events.
Data extraction and synthesis
For each study the specific outcome measures used were 
extracted with details of how the outcome was defined 
or described by the author (where reported) and, where 
relevant, the method of assessment, for example, child/
parent reported outcome measure, sleep diaries, actig-
raphy, polysomnography. Data were extracted by one 
researcher and checked by a second.
Outcomes were tabulated and grouped into core areas, 
then by outcome domain and specific outcome measure 
used. This was undertaken by a single researcher and 
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discussed with the wider team. The data were described 
in a narrative synthesis grouped by the categories.
Patient and public involvement
There was patient and public involvement in the deci-
sion by NIHR to commission the overall project focusing 
on sleep disturbances in children with neurodisabilities. 
Three parents of children with neurodisabilities, identi-
fied from an existing parent consultation group agreed to 
be involved with the project. They were invited to project 
team meetings, which took place three times during 
the project, and were consulted via email regarding the 
implications of the review findings. Their contributions 
provided useful contextual information. In addition, a 
member of a sleep charity, which supports parents, was 
involved at all stages of the project and is a co-author 
(VD) of the publication.
rEsults
Overview of included studies
After removal of duplicates 15 745 records were screened 
and 387 full-text records assessed for eligibility. Thir-
ty-nine studies (reported across 64 articles) were included: 
13 studies of melatonin, published between 1996 and 
2012 and 26 studies of parent-directed, environmental, 
dietary and complementary medicine interventions, 
published between 1991 and 2016 (table 1). The latter 
group of studies are referred to as non-pharmacolog-
ical for convenience. The studies were most commonly 
undertaken in the UK (36%) and USA (26%) followed by 
Australia (15%) and Canada (13%). Single studies were 
reported from the Netherlands, Italy, Israel and China. 
Study designs encompassed RCTs (both parallel-group 
and crossover), and for the non-pharmacological inter-
ventions, controlled before and after studies and one-arm 
before and after studies were also included.
The studies assessed five core outcome areas: child sleep, 
other child outcomes, parent-related, adverse events and 
process outcomes. All of the studies (n=39) reported at 
least one child sleep-related outcome: 19 (49%) reported 
other types of child outcomes such as daytime behaviour 
and cognition; and 14 reported parent/carer outcomes 
(36%) (table 1).
For the non-pharmacological studies, the first outcome 
measurement time points ranged from immediately 
post intervention to 2 months post intervention and five 
measured additional follow-up time points. All the mela-
tonin studies had a single follow-up time point immedi-
ately following the completion of the intervention, which 
ranged from 10 days to 12 weeks postrandomisation.
Child sleep outcomes
Table 2 reports the child sleep outcome measures used 
by at least one study. Fifty-four different measures of 
child related sleep outcomes were reported. There were 
five domains: global assessments of sleep (n=17 outcome 
measures); sleep initiation (n=10), sleep maintenance 
(n=18), sleep scheduling (n=4) and other outcomes 
(n=5).
In the melatonin studies, total sleep time (TST) was the 
most commonly reported global sleep outcome, reported 
by 12 of the 13 included studies (92%). Four reported 
TST derived from parent-completed sleep diaries and 
actigraphy13–16; three reported actigraphy derived data 
only17–19; six sleep diary derived data.20–25 The most 
common way to measure the sleep initiation domain was 
sleep onset latency (SOL, 85%); and within the sleep 
maintenance domain was night awakening (46%). As 
with TST, these outcomes were assessed using both actig-
raphy and sleep diary (reporting results of both or actig-
raphy only) or using sleep diary only. Sleep scheduling 
and parent-reported global measures of sleep were rarely 
reported in the melatonin studies (table 2).
For the non-pharmacological studies, the sleep 
outcome measures used were more disparate with only 
one measure reported by more than half the studies. The 
most commonly reported global measure of sleep (and 
the most commonly reported overall) was the parent-re-
ported Child Sleep Habits Questionnaire (CSHQ; 58%). 
TST calculated from actigraphy or parent-reported sleep 
diary data was much less commonly used (42%) compared 
with melatonin studies. Six studies reported actigraphy 
derived data,26–30 three reported parent completed sleep 
diary derived data,31–33 one reported actigraphy and diary 
derived data,34 and one reported data based on ‘semi-
weekly’ phone calls to parents.35 For the sleep initiation 
domain, the most commonly reported was SOL (39%); 
for sleep maintenance it was number of night awakenings 
(15%) and Wake After Sleep Onset (WASO; 19%); sleep 
scheduling was rarely reported. There was some overlap 
between pharmacological and non-pharmacological 
studies in the measures used, most commonly TST, sleep 
efficiency and SOL (table 2).
Even where studies were measuring the same outcome, 
there was variation in how this was measured, though 
often the method used was not specified. For example, 
in terms of wake time, one study used actigraphy and 
defined the outcome as the last epoch of actigraphically 
assessed immobility before the start of a 10 min consecu-
tive period of activity around the time of leaving bed18; 
two used parent-reported wake time using a sleep diary 
(no further definition provided)16 36; and one study used 
a momentary time sampling observation of children who 
were in-patients.37 WASO and night awakening both 
assess sleep maintenance, but different approaches to 
measurement were used. One study used actigraphy to 
measure night awakenings (definition not provided)38; 
one used a sleep diary (defining night awakenings as the 
number of awakenings per week that parents were aware 
of)33; and the other two did not provide a definition.35 36 
All studies reporting WASO used actigraphy, two of which 
defined WASO as a sum of the all wake epochs during 
the sleep period (total time awake during the night 
excluding the SOL period)28 39 (two did not specify how it 
was defined27 29). Where SOL was defined, there was also 
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Table 1 Summary of included studies
Study
Year
Country
Type of 
neurodisability Intervention Study design
Child outcomes
Sleep Other
Parent 
outcomes
Adverse 
events
Melatonin
  Appleton et al13 2012
UK
DD alone or with other 
condition
Melatonin Parallel RCT X X X X
  Camfield et al20 1996
Canada
Mixed Melatonin N of 1 crossover 
RCT
X
  Cortesi et al17 2012
Italy
ASD Melatonin Parallel RCT X X X
  Van der Heijden et al18 2007
Netherlands
ADHD Melatonin Parallel RCT X X X
  Dodge and Wilson23 2001
USA
Mixed Melatonin Crossover RCT X X
  Garstang and Wallis21 2006
UK
ASD with or without 
LD
Melatonin Crossover RCT X
  Hancock et al25 2005
UK
Tuberous sclerosis Melatonin Crossover RCT X X
  Jain et al16 2015
USA
Epilepsy Melatonin Crossover RCT X X X
  Jan et al24 2000
Canada
Mixed Melatonin Crossover RCT X X
  Wasdell et al14 2008
Canada
Mixed Melatonin Crossover RCT X X
  Weiss et al15 2006
Canada
ADHD Melatonin Crossover RCT x X X
  Wirojanan et al19 2009
USA
Mixed Melatonin Crossover RCT X X
  Wright et al22 2011
UK
Mixed Melatonin Crossover RCT X X
Non-pharmacological
  Adkins et al28 2012
USA
Mixed Parent-directed, non-tailored Parallel RCT X
  Austin et al36 2013
Australia
Mixed Parent-directed, tailored Before-after X X
  Beresford3 2012
UK
Mixed Parent-directed, tailored Parallel RCT X X
  Beresford3 
Intervention 2
2012
UK
Mixed Parent-directed, tailored Before-after X X
  Beresford3
  Intervention 3
2012
UK
Mixed Parent-directed non-tailored Before-after X X
  Beresford3
  Intervention 4
2012
UK
Mixed Parent-directed non-tailored Before-after X X
  Bramble60 1997
UK
Mixed Parent-directed non-tailored Before-after X X X
  Francis and 
Dempster31
2002
Australia
Mixed Valerian Crossover RCT X X
  Gringras et al34 2014
UK
Mixed Weighted blanket Crossover RCT X X X
  Guilleminault et al32 1993
USA
LD Light therapy+behavioural 
programme
Before-after X
  Hiscock et al27 2015
Australia
ADHD plus LD or ASD Parent-directed, tailored Parallel RCT X X X
  Johnson et al26 2013
USA
Autism and ASD Parent-directed, tailored Parallel RCT X
  Malow et al39 2014
USA
Mixed Parent-directed non-tailored Parallel RCT X X
  Montgomery et al61 2004
UK
Mixed Parent-directed non-tailored Parallel RCT X
  Moss et al62 2014
Australia
Mixed Parent-directed, tailored Parallel RCT X X X
Continued
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some variation. Definitions included time from lights out 
to sleep onset, the time from start of bedtime routine to 
sleep, the amount of time between when the child was put 
to bed and they fell asleep, and the time between taking 
melatonin and falling asleep.
Other child outcomes
Nineteen studies reported child outcomes other than 
sleep (table 3): 15 non-pharmacological studies (58%) 
and four pharmacological studies (31%). The domains 
assessed were child behaviour, quality of life, ADHD 
symptoms, cognition, school-related and other. Twen-
ty-nine different measures were used across the 18 studies 
and no single measure was used by more than three 
of the studies, though most by only one or two studies 
(table 3). The measures used ranged from validated tools 
to study-specific questionnaires.
It was not always clear whether studies had used the 
same version of a measure. For example, there are 
two versions of the Daily Parent Rating of Evening and 
Morning Behaviour (DREMB) scale40; the original 
version (DREMB) and a revised version (DREMB-R) with 
an item on irritability removed. Both studies using this 
outcome measure referenced the same source for the 
scale suggesting they used the same version. However, this 
could not be confirmed as only one gave details of the 
score range of the version used.27 41
Finally, we encountered a lack of clarity in reporting 
with respect to whether sub-scale and/or total scores 
were used. Thus, for the two studies which used the 
Child Behaviour Checklist, one reported the eight 
subscales scores plus a total score and daytime internal-
ising behaviour problem score (calculated from scores on 
three of the subscales),42 the other study presented insuf-
ficient information about the scores used.39
Adverse outcomes
Eleven melatonin studies (85%) recorded adverse events, 
with variation across studies in how data were collected 
and reported. Different approaches were described to 
measuring adverse events, with varying levels of standard-
isation, including: a standardised assessment tool which 
classified events into seven domains13; elicitation of adverse 
events during in-person/phone-call visits by the study 
team16 17; using study specific questionnaires completed by 
parents22 23; one reported using a standardised form15; open-
ended interviews14 18; one reported by parents using an 
unspecified method25; and in one study it was unclear how 
the data were collected.19 One non-pharmacological study 
reported a specific method of collecting on adverse events: 
making a 24-hour telephone line available to parents for 
reporting adverse events and gathering the information at 
weekly parents reviews (face-to-face or telephone).38 While 
other non-pharmacological studies reported some adverse 
events it was unclear whether there was a systematic method 
of gathering this information.
Parent outcomes
Fourteen non-pharmacological studies (54%) reported 
parent outcomes (table 4). A range of outcome domains 
Study
Year
Country
Type of 
neurodisability Intervention Study design
Child outcomes
Sleep Other
Parent 
outcomes
Adverse 
events
  Oriel et al35 2016
USA
ASD Aquatic exercise programme A-B-A X
  Peppers et al63 2016
USA
NR Non-comprehensive, parent-
directed
Before-after X X X
  Piazza et al64 1997
USA
Mixed Behavioural Parallel RCT X
  Quine and Wade65 1991
UK
LD Parent-directed, tailored Before-after X X X
  Reed et al29 2009
Canada
ASD Parent-directed non-tailored Before-after X X X
  Sciberras et al41 2011
Australia
ADHD Parent-directed, tailored Parallel RCT X X X
  Weiskop et al33 2005
Australia
Mixed Parent-directed, tailored Before-after X
  Wiggs and Stores30 1998
UK
Mixed Non-comprehensive, parent-
directed
RCT X X X
  Yehuda et al66 2011
Israel
ADHD Essential fatty acids Controlled before-
after
X X X
  Yu et al42 2015
Hong Kong
ASD and Asperger 
syndrome
Parent-directed non-tailored Before-after X X X
  Yu and Hong67 2012
China
LD Acupuncture and earpoint 
taping
Before-after X
10Definitions for how studies were classified as parent-directed and tailored/non-tailored are available in the effectiveness review report (www.journalslibrary.nihr.
ac.uk/programmes/hta/1421202/#/).
ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; DD, developmental delay; LD, learning disability; NR, not reported; RCT, 
randomised controlled trial.
Table 1 Continued 
 o
n
 8 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027205 on 19 June 2019. Downloaded from 
6 McDaid C, et al. BMJ Open 2019;9:e027205. doi:10.1136/bmjopen-2018-027205
Open access 
Table 2 Child sleep-related outcomes
Sleep outcome
Melatonin(n=13)
Non-pharmacological
(n=26)
All studies
(n=39)
Number of 
studies (%)
Studies measuring 
outcome
Number of 
studies (%)
Studies measuring 
outcome
Number of 
studies (%)
Global measures Total sleep time 12 (92) 13–23 25 11 (42) 26–33 35 38 39 23 (59)
Sleep efficiency 5 (38) 13 14 16–18 5 (19) 26–28 38 39 10 (26)
Longest sleep episode 1 (8) 14 0 (0) 1 (3)
Changes in sleep pattern 1 (8) 24 0 (0) 1 (3)
CSHQ 1 (8) 17 15 (58) 3 36 27 29 35 38 3941 42 62 63 67 16 (41)
SBQ 1 (8) 16 0 (0) 1 (3)
Parent-set child sleep goals 0 (0) 4 (15) 3 a, b, c, d 4 (10)
Composite Sleep Index (from modified version of Simonds 
and Parraga Sleep Questionnaire)
0 (0) 3 (12) 26 30 38 3 (8)
Goal Attainment Scale 0 (0) 2 (8) 33 62 2 (5)
Change in goal attainment rating 0 (0) 1 (4) 3 1 (3)
Sleep problems over past 4 weeks 0 (0) 1 (4) 27 1 (3)
Family Inventory of Sleep Habits 0 (0) 3 (12) 29 39 42 3 (8)
Composite Sleep Disturbance Score 0 (0) 1 (4) 61 1 (3)
Sleep quality (visual analogue scale) 0 (0) 1 (4) 31 1 (3)
Sleep improvement – child and parent rating scale 0 (0) 1 (4) 38 1 (3)
Quality of sleep—child smiley face rating 0 (0) 1 (4) 38 1 (3)
Quality of sleep—Likert rating scale 0 (0) 1 (4) 66 1 (3)
Sleep initiation Sleep onset latency 11 (85) 13–19 21–23 25 10 (39) 26 28 29 31 33 35 36 38 39 60 21 (54)
Bedtime 2 (15) 16 17 1 (4) 29 3 (8)
Sleep onset 2 (15) 18 19 1 (4) 37 3 (8)
Bedtime resistance 0 (0) 1 (4) 36 1 (3)
Bedtime routine 0 (0) 1 (4) 36 1 (3)
Number of pre-sleep disturbances 0 (0) 1 (4) 33 1 (3)
Falling asleep in own bed 0 (0) 1 (4) 33 1 (3)
Difficulty falling asleep (single item Likert scale) 1 (8) 18 0 (0) 1 (3)
Severity of bedtime settling problems (Behaviour 
Screening Questionnaire)
1 (4) 65 1 (3)
Time to settle at night 0 (0) 2 (8) 33 65 2 (5)
Sleep 
maintenance
Night awakenings 6 (46) 14 19 20 22 23 25 5 (19) 33 35 36 38 64 11 (28)
Number of nights without waking 1 (8) 20 0 (0) 1 (3)
Wake time 2 (15) 16 18 2 (8) 36 37 4 (10)
Time spent moving during sleep period 1 (15) 18 0 (0) 1 (3)
Co-sleeping 0 (0) 2 (8) 33 36 2 (5)
Number of nights not sleeping in own bed 1 (4) 65 1 (3)
Wake After Sleep Onset 2 (15) 16 17 4 (15) 27–29 39 6 (15)
Severity of sleep problem (VAS) (incorporating disturbed 
sleep)
0 (0) 1 (4) 60 1 (3)
Movement during sleep 0 (0) 1 (4) 30 1 (3)
Movement index 0 (0) 1 (4) 30 1 (3)
Fragmentation index 0 (0) 1 (4) 30 1 (3)
Time spent awake during night 0 (0) 3 (12) 31 38 65 3 (8)
Proportion of nights with >1 wakening 0 (0) 1 (4) 38 1 (3)
Parent/caregiver reported ‘no’ or
‘mild’ sleep problems
0 (0) 1 (4) 41 1 (2.6)
Longest wake and sleep periods during 24 hours cycle 0 (0) 1 (4) 32 1 (3)
Time of night wakes and return to sleep 0 (0) 1 (4) 37 1 (3)
Hours of disturbed sleep 0 (0) 1 (4) 37 1 (3)
Sleep Disturbance Index 0 (0) 1 (4) 36 1 (3)
Continued
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were assessed, and measures used were not consistent. 
Domains included: parental mental health (three outcome 
measures across five studies), parenting (for example, 
perceived confidence, efficacy or knowledge in relation 
to managing their child’s sleep problem) (five outcome 
measures across nine studies), quality of parental sleep 
(six outcome measures across three studies) and a range 
of other outcomes including attendance at work and locus 
of control (three measures across four studies). One mela-
tonin study assessed parent outcomes; specifically, it used 
the Epworth Sleepiness Scale to assess parental daytime 
sleepiness.13
Process outcomes
Several other outcomes and process measures were 
reported; related to adherence, feasibility of delivery, 
acceptability and experiences of receiving the intervention. 
These included: adherence to treatment (based on medi-
cation count (pharmacological studies only), intervention 
sessions attended, adherence to specific components of 
the intervention; withdrawal from study); various study-spe-
cific individual items or questionnaires to ascertain parents 
views about specific aspects of the intervention or overall 
views, for example, the proportion of participants rating 
treatment on a five point rating scale from ‘too tough’ to 
‘too soft’; rating of overall treatment helpfulness (visual 
analogue scale) and specific components of the interven-
tion; study specific Caregivers Acceptance of Treatment 
Survey (Likert Scale response format); a modified version 
of the Program Evaluation Questionnaires and qualita-
tive interviews. There was variation in the extent to which 
this information was reported in a standardised way, for 
example, limited detail in the methods used.
DIsCussIOn
Principal findings
The findings suggest a strong imperative to develop a 
core outcome set to be used in trials in this field. Over 
70 different outcome measures were reported across 39 
studies, the vast majority of measures reported by three 
or fewer studies. This greatly impedes analysis of data 
in systematic reviews due to lack of comparability across 
studies. It also makes it difficult to assess the likelihood 
of selective outcome reporting, with the associated risks 
of overestimating intervention effectiveness. It is unlikely 
that all these measures have equal importance for chil-
dren and parents, leading to uncertainty when making 
judgements about the relevance of specific study results.
There were five core areas assessed in the included 
studies: child sleep (six domains); other child outcomes 
(five domains); parent outcomes (four domains) 
adverse events and process measures. This suggests some 
consensus at the broadest level about what is relevant 
to measure; however, as the classification became more 
granular the diversity increased.
There was overlap between pharmacological and 
non-pharmacological studies in terms of the child sleep 
domains assessed and, to some extent, the measures 
used, reflecting the fact that, regardless of mechanism, a 
key target of both types of intervention was some aspect 
of child sleep. However, compared with the melatonin 
studies, there was more focus in the non-pharmacological 
studies on the core areas of child non-sleep outcomes, 
parent outcomes and family experience. This reflects 
the complex nature of these interventions, with parent 
understanding and perceived competency in managing 
their child’s sleep being implicit in the mechanism of 
action. The parent outcome domains were mental health, 
parenting (perceived confidence, efficacy or knowledge) 
and quality of sleep. Arguably, it is surprising that more 
studies of parent-directed interventions did not assess 
impact on parental perceived competence/confidence 
and that melatonin studies have not taken as family-cen-
tred approach to assessing the effects of the intervention 
in this population.
The most widely used outcome measure in the mela-
tonin studies was TST (measured using actigraphy and/
or sleep diary) and in the non-pharmacological studies 
was the CSHQ. Although they are both within the core 
Sleep outcome
Melatonin(n=13)
Non-pharmacological
(n=26)
All studies
(n=39)
Number of 
studies (%)
Studies measuring 
outcome
Number of 
studies (%)
Studies measuring 
outcome
Number of 
studies (%)
Sleep scheduling Naptime 1 (8) 17 0 (0) 1 (3)
Napping 0 (0) 1 (4) 36 1 (3)
Distribution of sleep bouts during 24 hours cycle 0 (0) 1 (4) 32 1 (3)
Degree of fatigue during the day—Likert rating scale 0 (0) 1 (4) 66 1 (3)
Interdaily stability 1 (8) 18 0 (0) 1 (3)
Other Interdaily variability 1 (8) 18 0 (0) 1 (3)
L5 1 (8) 18 0 (0) 1 (3)
Arousal Index (AASM) 1 (8) 16 0 (0) 1 (3)
Percentage of time in each sleep stage 1 (8) 16 0 (0) 1 (3)
a, intervention 1; AASM Arousal Index; b, intervention 2; c, intervention 3; CSHQ Child Sleep Habits Questionnaire; d, intervention 4; SBQ Sleep Behaviour Questionnaire; VAS 
Visual Analogue Scale.
Table 2 Continued 
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domain of child sleep and provide a global assessment, 
they differ considerably in level of objectivity, aspects of 
sleep assessed, feasibility and cost.43 They could be viewed 
as complementary measures to be used together, though 
only six studies used both. Even among these more 
common outcome measures there was variation between 
studies in how they were used. Lack of standard scoring 
rules and variation in definitions used for actigraphy-de-
rived outcomes has been identified as an area of concern, 
which is supported by our research.44
Adverse events were reported in the majority of mela-
tonin trials but rarely considered in the non-pharmaco-
logical studies. Standardisation of the reporting and data 
collection methods for adverse events in future trials is 
important to understand the safety of pharmacological 
interventions. This also has relevance for non-pharmaco-
logical studies as well, where interventions may have unin-
tended consequences.45–47
The diversity of outcome measures used significantly 
limited both the narrative and quantitative syntheses 
Table 3 Other child outcomes
Outcome
Melatonin
(n=13)
Non-pharmacological
(n=26)
All
(n=39)
Number of 
studies (%)
Studies 
measuring 
outcome
Number of 
studies (%)
Studies 
measuring 
outcome
Number of 
studies (%)
Behaviour Daily Parent Rating of Evening and Morning Behaviour 
Scale
0 (0) 2 (8) 17 41 2 (5)
Aberrant Behaviour Checklist 1 (8) 13 2 (8) 30 38 3 (8)
Behaviour Problem Index 0 (0) 2 (8) 60 65 2 (5)
Child Behaviour Checklist 1 (8) 18 2 (8) 39 42 3 (8)
Repetitive Behaviour Scale–Revised 0 (0)0 2 (8) 29 39 2 (5)
Child daytime behaviour (based on diary) 0 (0) 1 (4) 31 1 (3)
Developmental Behaviour Checklist-Parent Version 0 (0) 2 (8) 36 62 2 (5)
Sensory Behaviour Questionnaire (unpublished) 0 (0) 1 (4) 38 1 (3)
Behaviour Assessment System for Children-Parent Rating 
Scale
1 (8) 16 0 (0) 1 (3)
Quality of life Paediatric Quality of Life Inventory 4.0 1 (8) 13 3 (12) 27 39 41 4 (10)
Quality of Life in Childhood Epilepsy 1 (8) 16 0 (0) 1 (3)
Level of good mood in general (Likert scale) 1 (8) 15 1 (4) 66 2 (5)
TNO-AZL Quality of Life Questionnaire 1 (8) 18 0 (0) 1 (3)
ADHD 
symptoms
Vanderblit ADHD Symptom Checklist 0 (0) 1 (4) 63 1 (3)
ADHD Rating Scale IV 0 (0) 2 (8) 27 41 2 (5)
Conner’s Attention Deficit Scale–Parent Version 1 (8) 15 0 (0) 1 (3)
Cognitive Ability to concentrate during the day, mainly at school 
(Likert scale)
0 (0) 1 (4) 66 1 (3)
Working memory test battery* 0 (0) 1 (4) 27 1 (3)
Sustained attention dots task-completion time 1 (8) 18 0 (0) 1 (3)
Sustained attention dots task-inaccuracy† 1 (8) 18 0 (0) 1 (3)
Erikson Task–reaction time and error incidence‡ 1 (8) 18 0 (0) 1 (3)
School-
related
Homework completion (Likert scale) 0 (0) 1 (4) 66 1 (3)
School attendance 0 (0) 2 (8) 27 41 2 (5)
Teacher’s Report Form 1 (8) 18 0 (0) 1 (3)
Other Meal times 0 (0) 1 (4) 36 1 (3)
Parent report of other professional help sought 0 (0) 1 (4) 27 1 (3)
Parental Concerns Questionnaire 0 (0) 1 (4) 29 42 1 (3)
Strength and Difficulties Questionnaire 0 (0) 1 (4) 27 1 (3)
Parent and teacher reported core problems§ 1 (8) 18 0 (0) 1 (3)
*Backwards digit recall, counting recall, listening recall.
†Percentage of misses plus false alarms relative to the total number of trials.
‡Reaction time and error incidence between congruent and incongruent tasks.
§Core problems were spontaneously and individual defined by parents.
ADHD, attention deficit hyperactivity disorder.
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conducted for the review of the effectiveness of these 
interventions.9 Our findings are consistent with the 
results of studies in other fields exploring the extent 
of consistency of outcome measures used and in other 
evidence syntheses.48 49
unanswered questions and future research
A minimum core outcome set for use in effectiveness 
studies would greatly assist the usefulness of research 
in this field. This need not restrict researchers using 
outcome measures outside the core outcome set, where 
relevant to the specific study.50 An agreed minimum core 
outcome set would improve the ability to make compari-
sons between studies and ensure that the outcomes being 
used in studies are of relevance to children, their parents 
and also the healthcare professionals and others involved 
in providing support. Although sleep has been identified 
as an important outcome by young people with neurodis-
abilities and their parents it remains unclear what aspects 
of sleep are most important to them, for example whether 
it is the child’s total amount of sleep time, when they 
sleep, how many times they wake during the night etc. 
The importance to them of improving other outcomes 
such as child daytime behaviour or parental outcomes 
as part of sleep management interventions and which 
should be prioritised is also unclear.51
Effectiveness research that does not assess relevant 
and important outcomes is a source of avoidable waste.52 
The core outcome set should be developed in consul-
tation with parents and carers, children themselves 
where possible, and healthcare professionals and others 
involved in supporting parents and children, using a 
structured process such as that developed by the COMET 
Group.8 It is currently unclear whether the outcomes 
being assessed in studies evaluating sleep disturbance 
interventions are those that are important to families, 
both in terms of children’s sleep outcomes and parents’ 
sleep outcomes. Research in other fields has shown a 
disparity between the outcomes important to patients 
and those that are assessed in intervention studies.49 53 54 
Development of a core outcome set should be interna-
tional in scope to ensure future widespread adoption. 
In addition to identifying core outcomes, consensus 
will be required regarding appropriate measurement 
instruments. This should draw on appropriate methods 
to ensure selection of reliable and valid measures 
such as those used by the COSMIN initiative.55 Factors 
such as feasibility and respondent burden will also be 
important to consider. It will also be necessary to draw 
on existing comparative evidence on how objective and 
subjective sleep outcome measures perform, and the 
extent to which they are capturing unique dimensions 
of sleep.56 57 While child-report measures exist, work 
on their psychometric properties is limited and none 
appear to have been developed for children with any 
significant degree of learning difficulty.58 The heteroge-
neity in outcome measures used by studies in our review 
was compounded by the variation across studies in the 
clarity of information provided on how some outcomes 
Table 4 Parent/carer outcomes (non-pharmacological studies n=26)
Domain Outcome measure
Number of 
studies (%)
Studies 
measuring 
outcome
Parental mental health 
and well-being
Depression Anxiety Stress Scales 2 (8) 27 41
The Parenting Stress Index-Short Form 3 (12) 29 42 62
The Malaise Inventory 3 (12) 30 60 65
Parenting (eg, Perceived 
confidence efficacy or 
knowledge)
Perceived ability to control own and partner’s sleep difficulties (visual analogue 
scale)
1 (4) 30
Parental satisfaction with their ability to cope with their child’s sleep (Likert scale) 1 (4) 30
Parent satisfaction with child’s sleep 1 (4) 30
Parenting Sense of Competence scale (plus satisfaction and efficacy subscales) 5 (19) 3a,b,c,d 39
Knowledge of Behavioural Principles as Applied to Children 1 (4) 65
Parental sleep Maternal Sleep Scale 1 (4) 60
Pittsburgh Sleep Quality Index 1 (4) 42
Maternal total sleep time (actigraphy) 1 (4) 30
Other actigraphy measures of sleep (sleep period, activity score, movement 
index, fragmentation index)
1 (4) 30
Epworth Sleepiness Scale 1 (4) 30
Parental satisfaction with own sleep (Likert scale) 1 (4) 30
Other Work attendance (number of days missed or late for work) 2 (8) 27 41
Parent Satisfaction Likert Survey 1 (4) 63
Parental locus of Control 1 (4) 30
a, intervention 1; b, intervention 2; c, intervention 3; d, intervention 4. 
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were measured. Future research should follow appro-
priate reporting guidelines.59
A key decision point at the outset would be whether 
a core outcome set should be developed separately for 
pharmacological and non-pharmacological interven-
tions. We suggest that an appropriate approach would 
be to have a minimum core outcome set common across 
interventions with additional outcomes agreed where 
relevant for the two types of interventions. For parent-di-
rected interventions, children’s sleep outcomes are medi-
ated by parent outcomes achieved by the intervention 
(for example, parental acquisition of new knowledge and 
understanding of sleep, training in managing sleep distur-
bance). Formalising and refining a theory of change for 
such interventions would support and inform the devel-
opment of a core outcome set. This is relevant for both 
child and parent outcomes. Additionally, consideration is 
required of the variation across different types of neuro-
disability, where there may be desirable outcomes for 
one group not shared by other groups. The alternatives 
are to develop separate core outcome sets for children 
with sleep disturbance for each neurodisability or to have 
an overall consensus building exercise that prioritises a 
minimum core outcome set across conditions, with addi-
tional condition-specific outcomes identified. The latter 
is likely to be more feasible from a resource perspective.
Consistency in follow-up time points across studies of 
similar interventions, at least at the primary follow-up 
point, is required in order to support comparisons 
between studies in future systematic reviews and 
meta-analyses. This will require reaching consensus with 
regard to the most clinically meaningful follow-up time 
points, and whether evaluations should also seek to inves-
tigate maintenance of outcomes. Again, for non-pharma-
cological studies in particular, this would benefit from 
being based on an evidence-informed theory of change 
as the implementation of newly acquired knowledge and 
skills in managing a child’s sleep may take time to have 
an effect. The final follow-up time-point for most studies 
in our effectiveness review only allowed consideration of 
short-term outcomes. Future studies need to consider 
what longer-term follow-ups should be incorporated into 
study designs.
strengths and weaknesses of the study
The systematic review included a wide range of neuro-
disabilities and interventions in children aged 18 years or 
under. It therefore provides a comprehensive overview 
of the outcome domains assessed in this field of research 
and the outcome measures being used. However, we 
may have under-estimated the range of outcomes being 
assessed as this work was undertaken as part of a system-
atic review of effectiveness. Thus, although the outcomes 
of interest were very broad we did not exhaustively include 
all outcomes; therefore, we may have failed to identify 
some outcomes, for example some physiological aspects 
of sleep. In addition, we assigned the measures to one of a 
number of outcome domains, others doing the same task 
may allocate differently or attribute to different domains. 
However, these factors are unlikely to change the conclu-
sions. The description of outcome domains and measures 
used provides important evidence for the field in moving 
towards developing a core outcome set. While these 
will contribute to the development of a list of outcomes 
for a Delphi survey, as a first stage of developing a core 
outcome set, it is important that this is supplemented 
by the views of parents and children, healthcare profes-
sionals involved in designing and delivering interventions 
and researchers working in the field.
COnClusIOn
There is a lack of consistency between studies in the 
outcome measures used to assess the effectiveness of 
interventions for non-respiratory sleep disturbances in 
children with neurodisabilities. This hampers evidence 
synthesis and creates uncertainty about the relevance 
of study findings to parents and children. A minimum 
core outcome set, with international consensus, should 
be developed in consultation with parents, children and 
young people, and those involved in supporting families.
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